Kadhim AA, Jamal MY, Karim AK. Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development and Clinical Outcomes in an Iraqi Cohort. Al-Rafidain J Med Sci [Internet]. 2025 Oct. 6 [cited 2026 May 25];9(2):83-9. Available from: https://www.ajms.iq/index.php/ALRAFIDAIN/article/view/2352